9.56
price down icon0.52%   -0.05
after-market Dopo l'orario di chiusura: 9.54 -0.02 -0.21%
loading
Precedente Chiudi:
$9.61
Aprire:
$9.7
Volume 24 ore:
3.97M
Relative Volume:
0.93
Capitalizzazione di mercato:
$877.35M
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-1.7445
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
+3.91%
1M Prestazione:
+2.52%
6M Prestazione:
-20.13%
1 anno Prestazione:
-58.78%
Intervallo 1D:
Value
$9.51
$10.14
Intervallo di 1 settimana:
Value
$8.875
$10.14
Portata 52W:
Value
$5.90
$28.18

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Nome
Intellia Therapeutics Inc
Name
Telefono
857-285-6200
Name
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Name
Dipendente
598
Name
Cinguettio
@intelliatweets
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
NTLA's Discussions on Twitter

Confronta NTLA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
9.56 877.35M 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-21 Aggiornamento Wolfe Research Peer Perform → Outperform
2025-03-05 Iniziato H.C. Wainwright Buy
2025-02-28 Downgrade Goldman Neutral → Sell
2025-02-28 Downgrade JP Morgan Overweight → Neutral
2025-01-27 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-02-23 Downgrade Goldman Buy → Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-04-13 Iniziato Canaccord Genuity Buy
2023-03-21 Iniziato Bernstein Outperform
2023-03-14 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2023-01-24 Aggiornamento Citigroup Sell → Neutral
2023-01-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 Iniziato Morgan Stanley Overweight
2022-09-21 Iniziato JP Morgan Overweight
2022-09-01 Iniziato Citigroup Sell
2022-06-17 Iniziato BMO Capital Markets Market Perform
2022-06-16 Iniziato BofA Securities Buy
2022-04-28 Iniziato Credit Suisse Outperform
2022-02-18 Iniziato William Blair Outperform
2022-02-07 Aggiornamento Oppenheimer Perform → Outperform
2022-01-31 Iniziato Cowen Outperform
2022-01-07 Iniziato Piper Sandler Overweight
2021-10-05 Iniziato Guggenheim Buy
2021-09-24 Iniziato Stifel Buy
2021-06-28 Reiterato H.C. Wainwright Buy
2021-06-11 Iniziato H.C. Wainwright Buy
2021-05-07 Aggiornamento ROTH Capital Neutral → Buy
2021-05-04 Iniziato RBC Capital Mkts Outperform
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-22 Downgrade Robert W. Baird Outperform → Neutral
2020-10-27 Iniziato Truist Buy
2020-10-14 Iniziato Wells Fargo Overweight
2020-09-18 Iniziato Goldman Buy
2020-02-28 Aggiornamento Oppenheimer Perform → Outperform
2020-02-14 Downgrade Wedbush Outperform → Neutral
2019-11-01 Aggiornamento Raymond James Mkt Perform → Outperform
2019-07-09 Iniziato Robert W. Baird Outperform
2019-06-10 Iniziato ROTH Capital Neutral
2019-05-03 Aggiornamento Wedbush Neutral → Outperform
2019-04-12 Iniziato Evercore ISI Outperform
2018-11-02 Downgrade Wedbush Outperform → Neutral
2018-10-29 Iniziato Credit Suisse Neutral
2018-09-21 Iniziato Raymond James Mkt Perform
2018-05-15 Aggiornamento Chardan Capital Markets Neutral → Buy
2018-03-08 Iniziato JMP Securities Mkt Outperform
2017-11-01 Reiterato Jefferies Buy
2017-06-22 Ripresa Jefferies Buy
2017-03-28 Iniziato Chardan Capital Markets Buy
2016-08-05 Aggiornamento Jefferies Hold → Buy
Mostra tutto

Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie

pulisher
Jun 18, 2025

Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News

Jun 18, 2025
pulisher
Jun 17, 2025

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener

Jun 16, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 14, 2025

Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 10, 2025

California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

(NTLA) Investment Report - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
May 31, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus

May 31, 2025
pulisher
May 30, 2025

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga

May 30, 2025
pulisher
May 30, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN

May 30, 2025
pulisher
May 30, 2025

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News

May 30, 2025
pulisher
May 30, 2025

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

May 30, 2025
pulisher
May 30, 2025

Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter

May 30, 2025
pulisher
May 30, 2025

Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush - Defense World

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus

May 30, 2025
pulisher
May 29, 2025

Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar

May 29, 2025
pulisher
May 29, 2025

ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia adverse event could resurface questions, says JPMorgan - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN

May 29, 2025

Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Intellia Therapeutics Inc Azioni (NTLA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Clark Eliana
EVP, Chief Technical Officer
Mar 04 '25
Sale
8.99
679
6,104
95,369
BASTA JAMES
EVP, General Counsel
Mar 04 '25
Sale
8.99
2,572
23,122
111,925
Bhanji Muna
Director
Jan 29 '25
Sale
9.97
265
2,642
19,468
Dube Michael P
VP, Chief Accounting Officer
Jan 03 '25
Sale
12.18
1,372
16,711
45,640
BASTA JAMES
EVP, General Counsel
Jan 03 '25
Sale
12.18
7,074
86,161
74,497
Lebwohl David
EVP, Chief Medical Officer
Jan 03 '25
Sale
12.18
9,557
116,404
87,666
Hicks Derek
EVP, Chief Business Officer
Jan 03 '25
Sale
12.18
6,502
79,194
59,878
LEONARD JOHN M
President and CEO
Jan 03 '25
Sale
12.18
26,807
326,509
941,115
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Jan 03 '25
Sale
12.18
8,966
109,206
77,388
Clark Eliana
EVP, Chief Technical Officer
Jan 03 '25
Sale
12.18
7,422
90,400
64,048
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):